Prevention of Antibiotic-Nonsusceptible Invasive Pneumococcal Disease with the 13-Valent Pneumococcal Conjugate Vaccine

Clinical Infectious Diseases

Volumn 62, Issue 9, 2016, Pages 1119-1125

  Tomczyk, Sara ^a,b   Lynfield, Ruth ^e   Schaffner, William ^f   Reingold, Arthur ^g   Miller, Lisa ^h   Petit, Susan ^h   Holtzman, Corinne ^e   Zansky, Shelley M ^h   Thomas, Ann ⁱ   Baumbach, Joan ^h   Harrison, Lee H ^j   Farley, Monica M ^c,d   Beall, Bernard ^b   McGee, Lesley ^b   Gierke, Ryan ^b   Pondo, Tracy ^b   Kim, Lindsay ^b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e MINNESOTA DEPARTMENT OF HEALTH   (United States)

^f VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h Department of Public Health ^*  (United States)

ⁱ Oregon Dept of Human Svcs   (United States)

^j JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

more..

Author keywords

Antibiotic nonsusceptibility; pneumococcal conjugate vaccine; resistance; Streptococcus pneumoniae

Indexed keywords

CEPHALOSPORIN DERIVATIVE; GLYCOPEPTIDE; MACROLIDE; PENICILLIN DERIVATIVE; PNEUMOCOCCUS VACCINE; QUINOLONE DERIVATIVE; TETRACYCLINE DERIVATIVE; 13-VALENT PNEUMOCOCCAL VACCINE; ANTIINFECTIVE AGENT;

ADULT; AGED; ANTIBIOTIC NONSUSCEPTIBLE INVASIVE PNEUMOCOCCAL DISEASE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BROTH DILUTION; CHILD; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; SEROTYPE; STREPTOCOCCUS PNEUMONIAE; ADOLESCENT; ANTIBIOTIC RESISTANCE; DRUG EFFECTS; EVALUATION STUDY; GENETICS; IMMUNOLOGY; INFANT; ISOLATION AND PURIFICATION; MIDDLE AGED; NEWBORN; PNEUMOCOCCAL INFECTIONS; PRESCHOOL CHILD; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; SEROGROUP; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84966657359     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciw067     Document Type: Article

References (36)

1. O'Brien KL, Wolfson LJ, Watt JP, et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009; 374:893-902.
2. Griffin MR, Zhu Y, Moore MR, Whitney CG, Grijalva CG. U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination. N Engl J Med 2013; 369:155-63.
3. Feikin DR, Schuchat A, Kolczak M, et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am J Public Health 2000; 90:223-9.
4. Centers for Disease Control and Prevention. Pneumococcal disease. Available at: http://www.cdc.gov/pneumococcal/clinicians/clinical-features.html. Accessed 7 October 2013.
5. Madhi SA, Kuwanda L, Cutland C, Klugman KP. The impact of a 9-valent pneumococcal conjugate vaccine on the public health burden of pneumonia in HIVinfected and-uninfected children. Clin Infect Dis 2005; 40:1511-8.
6. Cutts FT, Zaman SM, Enwere G, et al. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet 2005; 365:1139-46.
7. Black SB, Shinefield HR, Ling S, et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr Infect Dis J 2002; 21:810-5.
8. Whitney CG. More evidence for use of pneumococcal conjugate vaccines. Lancet 2013; 381:182-3.
9. Jackson M, Neuzil K, Thompson W, et al. The burden of community-acquired pneumonia in seniors: results of a population-based study. Clin Infect Dis 2004; 39:1642-50.
10. Pilishvili T, Lexau C, Farley MM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010; 201:32-41.
11. Huang SS, Johnson KM, Ray GT, et al. Healthcare utilization and cost of pneumococcal disease in the United States. Vaccine 2011; 29:3398-412.
12. Centers for Disease Control and Prevention. Active bacterial core surveillance report: Streptococcus pneumoniae. Available at: http://www.cdc.gov/abcs/reportsfindings/survreports/spneu09.pdf. Accessed 7 October 2013.
13. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. Atlanta, GA: Centers for Disease Control and Prevention, 2013.
14. United States Department of Health and Human Services. Healthy people 2020. Washington, DC: Government Printing Office, 2008.
15. Hampton LM, Farley MM, Schaffner W, et al. Prevention of antibioticnonsusceptible Streptococcus pneumoniae with conjugate vaccines. J Infect Dis 2012; 205:401-11.
16. Hicks LA, Chien YW, Taylor TH Jr, Haber M, Klugman KP. Outpatient antibiotic prescribing and nonsusceptible Streptococcus pneumoniae in the United States, 1996-2003. Clin Infect Dis 2011; 53:631-9.
17. Centers for Disease Control and Prevention. Active bacterial core surveillance population. Available at: http://www.cdc.gov/abcs/methodology/surv-pop.html. Accessed 7 October 2013.
18. United States Census Bureau. US and world population clock. Available at: http://www.census.gov/popclock/?intcmp=home-pop. Accessed 7 October 2013.
19. Park IH, Moore MR, Treanor JJ, et al. Differential effects of pneumococcal vaccines against serotypes 6A and 6C. J Infect Dis 2008; 198:1818-22.
20. Hampton LM, Farley MM, Schaffner W, et al. Prevention of antibioticnonsusceptible Streptococcus pneumoniae with conjugate vaccines. J Infect Dis 2011; 205:401-11.
21. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: twenty-second informational supplement. CLSI Document M100-S22. Wayne, PA: Clinical and Laboratory Standards Institute, 2012.
22. Little RJ, Rubin DB. Causal effects in clinical and epidemiological studies via potential outcomes: concepts and analytical approaches. Annu Rev Public Health 2000; 21:121-45.
23. Moore MR, Link-Gelles R, Schaffner W, et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis 2015; 15:301-9.
24. Hackel M, Lascols C, Bouchillon S, Hilton B, Morgenstern D, Purdy J. Serotype prevalence and antibiotic resistance in Streptococcus pneumoniae clinical isolates among global populations. Vaccine 2013; 31:4881-7.
25. Dagan R. Impact of pneumococcal conjugate vaccine on infections caused by antibiotic-resistant Streptococcus pneumoniae. Clin Microbiol Infect 2009; 15(suppl 3):16-20.
26. Tyrrell GJ, Lovgren M, Chui N, et al. Serotypes and antimicrobial susceptibilities of invasive Streptococcus pneumoniae pre-and post-seven valent pneumococcal conjugate vaccine introduction in Alberta, Canada, 2000-2006. Vaccine 2009; 27:3553-60.
27. Pelton SI, Huot H, Finkelstein JA, et al. Emergence of 19A as virulent and multidrug resistant pneumococcus in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine. Pediatr Infect Dis J 2007; 26:468-72.
28. Beall BW, Gertz RE, Hulkower RL, Whitney CG, Moore MR, Brueggemann AB. Shifting genetic structure of invasive serotype 19A pneumococci in the United States. J Infect Dis 2011; 203:1360-8.
29. Moore MR, Gertz RE Jr, Woodbury RL, et al. Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005. J Infect Dis 2008; 197:1016-27.
30. Richter SS, Diekema DJ, Heilmann KP, Dohrn CL, Riahi F, Doern GV. Changes in pneumococcal serotypes and antimicrobial resistance after introduction of the 13-valent conjugate vaccine in the United States. Antimicrob Agents Chemother 2014; 58:6484-9.
31. Dellit TH, Owens RC, McGowan JE, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007; 44:159-77.
32. Fauci AS, Marston lD. The perpetual challenge of antimicrobial resistance. JAMA 2014; 311:1853-4.
33. Hicks LA, Monnet DL, Roberts RM. Increase in pneumococcus macrolide resistance, USA. Emerg Infect Dis 2010; 16:896-7.
34. Hicks LA, Bartoces MG, Roberts RM, et al. US outpatient antibiotic prescribing variation according to geography, patient population, and provider specialty in 2011. Clin Infect Dis 2015; 60:1308-16.
35. Centers for Disease Control and Prevention. Get Smart: Know when antibiotics work. Available at: http://www.cdc.gov/getsmart/. Accessed 22 June 2014.
36. White House Interagency Task Force for Combating Antibiotic-Resistant Bacteria. National action plan for combating antibiotic resistant bacteria. Washington, DC: The White House, 2015.